Nasdaq, Inc. NDAQ reported second-quarter 2021 adjusted earnings per share of $1.90, beating the Zacks Consensus Estimate of $1.73 by 9.8%. The bottom line increased 23.4% year over year.The improvement was primarily driven by organic growth, favorable changes in foreign exchange rates, margin expansion and solid segmental performance. Nasdaq noted that the solid results reflect strength of its diverse offerings and scalability of increasingly SaaS-oriented business model.Nasdaq, Inc. Price, Consensus and EPS Surprise Nasdaq, Inc. price-consensus-eps-surprise-chart | Nasdaq, Inc. QuotePerformance in DetailNasdaq’s revenues of $846 million increased 21% year over year. The upside was primarily attributable to a $104 million impact from organic growth, a $27 million increase from the inclusion of revenues from the acquisition of Verafin, and a $16 million increase from the impact of favorable changes in FX rates. The top line beat the Zacks Consensus Estimate by 2.7%.Adjusted operating expenses were $392 million, up 20% from the year-ago period owing to a $24 million organic increase, a $26 million impact of the Verafin acquisition and a $15 million increase from changes in FX rates.Operating margin of 54% expanded 100 basis points year over year.Nasdaq witnessed 135 IPOs in the second quarter, representing $32 billion in capital raised, including 88 operating company IPOs and 47 IPOs of special purpose acquisition companies. In the reported quarter, the Nasdaq welcomed 264 new listings.Segment DetailsNet revenues at Market Services were up 13% from the year-ago quarter to $312 million. This upside was largely due to higher revenues from equity derivative trading and clearing, cash equity trading, fixed income and commodities trading and clearing, and trade management services.Revenues at Corporate Services increased 22% year over year to $154 million, driven by higher listings services revenues as well as IR & ESG revenues.Investment Intelligence revenues rose 23% year over year to $263 million. Higher market data, index and analytics revenues drove the upside.Revenues at Market Technology increased 39% year over year to $117 million, largely due to higher revenues at marketplace infrastructure technology as well as anti-financial crime technology.Financial UpdateNasdaq had cash and cash equivalents of $430 million as of Jun 30, 2021, down from $2.8 billion at 2020-end level. Long-term debt decreased 1.1% from 2020-end level to $5.5 billion as of Jun 30, 2021.Capital DeploymentNasdaq returned $579 million in the first half of 2021, including $410 million in share repurchases and $169 million in dividends.As of Jun 30, 2021, Nasdaq had $1.459 billion remaining under its share repurchase authorization.GuidanceNasdaq provided 2021 non-GAAP operating expense guidance in the range of $1.59 billion to $1.62 billion.Non-GAAP tax rate is still estimated to be in the range of 25% to 27% in 2021.Zacks RankNasdaq currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.Upcoming ReleasesCME Group Inc. CME is slated to release second-quarter earnings on Jul 28. The Zacks Consensus Estimate for the bottom line is pegged at $1.59.Intercontinental Exchange Inc. ICE is scheduled to release second-quarter earnings on Jul 29. The Zacks Consensus Estimate for earnings is pegged at $1.16.Cboe Global Markets, Inc. CBOE is set to release second-quarter earnings on Jul 30. The Zacks Consensus Estimate for earnings is pegged at $1.35. Breakout Biotech Stocks with Triple-Digit Profit Potential The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases. Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.See these 7 breakthrough stocks now>>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Intercontinental Exchange Inc. (ICE): Free Stock Analysis Report CME Group Inc. (CME): Free Stock Analysis Report Nasdaq, Inc. (NDAQ): Free Stock Analysis Report Cboe Global Markets, Inc. (CBOE): Free Stock Analysis Report To read this article on Zacks.com click here.